Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04751838
Other study ID # KYLL-202011-114
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date October 30, 2020
Est. completion date March 30, 2021

Study information

Verified date February 2021
Source Qilu Hospital of Shandong University
Contact Luyao Gao
Phone 15165110975
Email 15165110975@163.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Acute heart failure (AHF) is one of the most common causes of hospitalization and life-threatening medical condition around worldwide. The AHF patients admitted to the intensive care unit (ICU) usually be critically ill with multiorgan failure, in which the kidneys are most frequently involved. The goals of treatment of AHF in ICU were to improve hemodynamic stability and organ perfusion, alleviate symptoms, and limit cardiac and renal damage, which can be achieved by continuous renal replacement therapy (CRRT), a continuous extracorporeal blood purification. CRRT can mimic urine output to slowly and continuously remove patient's plasma water, providing accurate volume control and hemodynamic stability. Acute Heart Failure Global Survey of Standard Treatment (ALARM-HF) study showed that hospital mortality of AHF patients was about 17.8% in the intensive care unit (ICU). But the patients undergoing CRRT, the mortality up to 45%-62.1%. For this reason, an early model or score to a screening of AHF patients undergoing CRRT who at high mortality risk is crucial, which can help clinicians to rapidly intervene and ameliorate disease outcomes. The most popular tools, especially that can predict mortality for critically ill patients, are the Acute Physiology Assessment and Chronic Health Evaluation II (APACHE II) scoring systems, and Simplified Acute Physiologic Score II (SAPS II). But variables in these scoring systems are complex, which was not convenient to assess at any time. Modified Early Warning Score (MEWS) , much more concise than APACHE II and SAPS II, not only can be used for early warning of the onset of AHF in patients with the risk of heart failure but also has a positive correlation with mortality in these patients. However, up to our knowledge, there was no scores or model to predict the in-hospital mortality of AHF patient undergoing CRRT. Based on the acute heart failure unit (AHFU) of Qilu Hospital and the medical information mart for intensive care III (MIMIC III) database, the investigators collected the data of AHF adults undergoing CRRT. The present study aimed to develop and validate a simple-to-use nomogram model comprised of independent prognostic variables for predicting in-hospital mortality in AHF adults undergoing CRRT by using multivariate logistic regression analysis. With this model, the investigators can guide the early screening of high-risk patients in in-hospital mortality.


Description:

The eligible patients randomly into training cohort and validation cohort. The univariate logistics regression analyses were performed to determine the independent risk characteristics in the training cohort of the presence of in-hospital all-cause death. Odds Ratios (ORs) and 95% confidence intervals (CIs) of these variables were estimated to quantify the strength of these associations. All variables that showed a univariate relationship with in-hospital mortality or that were considered clinically relevant were candidates for stepwise multivariate analysis in the training cohort. A nomogram model, producing by using the rms package, was formulated based on the results of independent risk factors in multivariate logistic regression. Based on the nomogram model, the total scores and prediction of in-hospital mortality risk of each patient were added by each eligible variable and then were converted to predicted probabilities both in the training cohort and validation cohort. To evaluated the model for the prediction value of in-hospital mortality, firstly, the investigators calculated the calibration of the model was measured by calibration with 1000 bootstrap samples to decrease the overfit bias. Model fitting was assessed using the Hosmer-Lemeshow test to evaluate the goodness of fit. Secondly, the Harrell concordance index (C index) and receiver operating characteristic curve (ROC curve) to evaluate the predictive performance and discrimination of the nomogram. The ROC curve analysis was used to calculate the optimal cutoff values that were determined by maximizing the Youden index. Third, the clinical effectiveness of the resulting model was evaluated by decision curve analysis (DCA), which was a method for evaluating alternative diagnostic or prognostic tools that had advantages over others[16]. The increase in the discriminative value of MEWS and the resulting model for mortality was assessed by the net reclassification index (NRI).


Recruitment information / eligibility

Status Recruiting
Enrollment 226
Est. completion date March 30, 2021
Est. primary completion date February 28, 2021
Accepts healthy volunteers No
Gender All
Age group 15 Years and older
Eligibility Inclusion Criteria: - Clinical diagnosis of acute heart failure - undergoing CRRT Exclusion Criteria: - died before CRRT

Study Design


Related Conditions & MeSH terms


Intervention

Other:
no intervention
no intervention

Locations

Country Name City State
China Qilu Hospital of Shandong University Jinan Shandong

Sponsors (1)

Lead Sponsor Collaborator
Qilu Hospital of Shandong University

Country where clinical trial is conducted

China, 

References & Publications (5)

Karkar A, Ronco C. Prescription of CRRT: a pathway to optimize therapy. Ann Intensive Care. 2020 Mar 6;10(1):32. doi: 10.1186/s13613-020-0648-y. Review. — View Citation

Macedo E, Mehta RL. Continuous Dialysis Therapies: Core Curriculum 2016. Am J Kidney Dis. 2016 Oct;68(4):645-657. doi: 10.1053/j.ajkd.2016.03.427. Epub 2016 May 28. — View Citation

Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P; ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016 Jul 14;37(27):2129-2200. doi: 10.1093/eurheartj/ehw128. Epub 2016 May 20. Erratum in: Eur Heart J. 2016 Dec 30;:. — View Citation

Ronco C, Ricci Z. Renal replacement therapies: physiological review. Intensive Care Med. 2008 Dec;34(12):2139-46. doi: 10.1007/s00134-008-1258-6. Epub 2008 Sep 13. Review. — View Citation

Schaubroeck HA, Gevaert S, Bagshaw SM, Kellum JA, Hoste EA. Acute cardiorenal syndrome in acute heart failure: focus on renal replacement therapy. Eur Heart J Acute Cardiovasc Care. 2020 Oct;9(7):802-811. doi: 10.1177/2048872620936371. Epub 2020 Jun 29. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary in-hospital mortality according to the state of departure from the hospital, if the patient died, named in-hospital mortality During hospitalization, an average of 20 days
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04080388 - How to Prevent Heart Failure Readmission by Using Lung Impedance Device (HOPE-HF Study) Phase 3
Active, not recruiting NCT04618601 - Diuretic and Natriuretic Effect of High-dose Spironolactone in Patients With Acute Heart Failure Phase 4
Recruiting NCT06142474 - SGLT2 Inhibitors in Patients With ADHF During Ventilator Weaning Phase 3
Active, not recruiting NCT05603247 - The SWISSHEART Failure Network (SHFN)
Recruiting NCT03169803 - Cardiac Output Autonomic Stimulation Therapy for Acute Heart Failure (COAST-AHF) N/A
Not yet recruiting NCT06273397 - Acetazolamide or Metolazone in Acute Heart Failure N/A
Recruiting NCT03542123 - Cardiac Output Autonomic Stimulation Therapy for Heart Failure - Hemodynamic Effects N/A
Completed NCT04878263 - Evaluation and Support Care Process Within the Care Pathway of Heart Failure Patients N/A
Not yet recruiting NCT06442280 - SGLT-2 Inhibitor and High-Dose Furosemide Plus Small-Volume Hypertonic Saline Solution in Acute HF Phase 4
Completed NCT04281849 - Balance, Aerobic Capacity, Mobility and Strength in Patients Hospitalized for Heart Failure (BAMS-HF) Program N/A
Not yet recruiting NCT04403659 - Telemonitoring of Patients Admitted in Hospital at Home With Acute Decompensated Heart Failure - Pilot Study N/A
Terminated NCT03574857 - Prospective Comparison of Metolazone Versus Chlorothiazide for Acute Decompensated Heart Failure With Diuretic Resistance Phase 4
Completed NCT03136198 - B-lines Lung Ultrasound Guided ED Management of Acute Heart Failure Pilot Trial Phase 2
Terminated NCT03746002 - Diuretic Effect of Metolazone Pre-dosing Versus Concurrent Dosing Phase 4
Active, not recruiting NCT03513653 - Strain for Risk Assessment and Therapeutic Strategies in Patients With Acute Heart Failure (STRATS-AHF) Registry
Recruiting NCT06092437 - Investigating a Tailored Diuretic Algorithm in Acute Heart Failure Patients N/A
Recruiting NCT05746923 - Lesser Poland Cracovian Heart Failure Registry
Recruiting NCT06414928 - Prognostic Model Heart Failure
Completed NCT04606927 - Pragmatic Urinary Sodium-based Treatment algoritHm in Acute Heart Failure N/A
Completed NCT03200860 - Effects of Empagliflozin on Clinical Outcomes in Patients With Acute Decompensated Heart Failure Phase 2